ClinicalTrials.gg
CompletedNCT02291926Updated May 10, 2017

Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect

A Phase 1 interventional study of Human umbilical cord mesenchymal stem cells in Cartilage Diseases and Osteoarthritis, sponsored by Shenzhen Hornetcorn Bio-technology Company, LTD. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-10.

Sponsored by Shenzhen Hornetcorn Bio-technology Company, LTD · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for articular cartilage defect of knee.

Read the detailed description

Human articular cartilage has limited repair potential.Cell-based strategies have explored chondrocytes and mesenchymal stem cells (MSCs) with extensive basic science and preclinical studies.However the concept of autologous chondrocyte implantation is not ideal,so the focus in cartilage repair is shifting toward mesenchymal stem cells.

To investigate the effects of hUC-MSC treatment for articular cartilage defects, 20 patients will be enrolled and receive 4 times of hUC-MSC transplantation.

02

Conditions studied

  • Cartilage Diseases
  • Osteoarthritis

Keywords

  • Human Umbilical Cord Mesenchymal Stem Cell
  • Mesenchymal Stem Cell
  • Osteoarthritis
03

In context

Cartilage Diseases

38 studies on the registry are indexed under Cartilage Diseases; 3 are open to participants now.

This study's enrollment of 20 is below the median of 100 across 24 interventional studies indexed under Cartilage Diseases.

Browse Cartilage Diseases studies →

Lead sponsor

Shenzhen Hornetcorn Bio-technology Company, LTD is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must consent in writing to participate in the study by signing and dating an document
  • Healthy patients with no major history of illness
  • Patients must have a diagnosis of osteoarthritis by radiographic criteria of Kellgren and Lawrence grade 2-4
  • Patients who needs invasive interventions of arthroplasty due to no response from existing pain medication
  • Patients must have had more than Grade 4 (0\~10 point numeric scale) pain at least for four months
  • Patient's damaged cartilage area should be in the range of 2-6cm2

Exclusion criteria

Exclusion Criteria:

  • Pregnant women or lactating mothers
  • Patients who have received any anti-inflammatory drugs including herb-drug within 14 days
  • Patients who received any drug by intra-articular injection for treatment within 2 months prior to this enrollment
  • Patients with positive human immunodeficiency () at screening indicative of current of pass infection
  • Impaired liver function, abnormal blood coagulation, combine other tumor or special condition
  • Patients who had participated in other clinical trials within three months prior to this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    hUC-MSC treatment

    Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.

    Biological: Human umbilical cord mesenchymal stem cells

Interventions

06

What researchers measure

Primary outcomes

  1. Severity of adverse events

    Adverse events were categorized using National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0 scale (NCI-CTCAE v4.0).

    Time frame: 12 months

Secondary outcomes

  1. Magnetic resonance imaging (MRI) of the knee

    The size, depth of cartilage defect, and regenerated cartilage were measured using MRI.

    Time frame: Before and 1,3,6,12 month after treatment

  2. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    Change in WOMAC pain score,composite score and function and stiffness index scores.

    Time frame: Before and 1,3,6,12 month after treatment

07

Study locations

1 site
  • The Fifth Affiliated Hospital Immunotherapy center
    Guangzhou, Guangdong 510000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Jul 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2014
First posted
Nov 17, 2014
Start
Dec 2014
Primary completionActual
Jul 2016
CompletionActual
Dec 2016
Last update
May 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02291926
Lead sponsor
Shenzhen Hornetcorn Bio-technology Company, LTD
Collaborators
Fifth Affiliated Hospital of Guangzhou Medical University
Responsible party
Sponsor
First posted
Nov 17, 2014
Start date
Dec 2014
Primary completion
Jul 2016
Completion
Dec 2016
Last update
May 10, 2017

Study contacts

Ping J Chen, Professor
principal investigator · Fifth Affiliated Hospital of Guangzhou Medical University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion